Pharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis

Area of Science:

• Pharmacology
• Genetics
• Psychiatry

Background:

• Panic disorder (PD) affects 20-40% of patients who are resistant to pharmacological treatments.
• Pharmacogenetics may offer insights into treatment resistance in PD.
• Current treatments for PD do not work for all patients.

Purpose of the Study:

• To assess the clinical utility of pharmacogenetic testing in patients with treatment-resistant PD.
• To gather preliminary data on the effectiveness of pharmacogenetic testing for PD.
• To explore genetic markers associated with PD treatment outcomes.

Main Methods:

• An observational study included twenty patients with treatment-resistant PD.
• Commercial pharmacogenetic testing was performed on all participants.
• The testing panel analyzed gene polymorphisms including CYP, EPHX1, UGT1A4, UGT2B15, ABCB1, ADRA2A, ANKK1, COMT, DRD2, FKBP5, GRIK4, GSK3B, HTR1A, HTR2A, HTR2C, MC4R, OPRM1, SCN1A, SLC6A4, and MTHFR.

Main Results:

• Pharmacogenetic tests indicated a reduced chance of response in 30% of patients.
• Tests suggested very low serum drug levels in 20% of patients.
• Reduced MTHFR enzyme activity was predicted in 74% of patients, and ABCB1 gene alleles linked to drug resistance were found in 90%.

Conclusions:

• Commercial pharmacogenetic testing did not reliably predict negative treatment outcomes in most PD patients.
• The association between PD treatment resistance and CYP2C19, MTHFR, and ABCB1 genes warrants further investigation.
• Pharmacogenetics may play a role in understanding and treating PD, but more research is needed.